Skip to main content


German company Boehringer Ingelheim inaugurated their newly enlarged pharmaceutical production plant in Sant Cugat del Vallès (Barcelona, Spain) yesterday afternoon, which will double their manufacturing capacity. This culminates Boehringer Ingelheim’s investment of €30.8 millions in Catalonia over the past two years, which will also entail a staff of more than 100 workers in the middle term.

President of the Government of Catalonia Artur Mas presided over the event with Mayor Mercè Conesa; the Catalan Government’s delegate in Barcelona, Salvador Jorba; and BIESA CEO and president of the Board, Manuel García Garrido and Lluís Llubià, respectively.

Mas explained that Catalonia needs companies that grow and generate wealth, because “this is the way to pull out of the complicated situation we are currently in.” The head of the executive branch, after visiting the pharmaceutical company’s facility, which has been enlarged to encompass eight sterile manufacturing lines for injectables, set this company as an example of “companies that grow in difficult times, innovate, export and create jobs.”

The plant has been enlarged in order to meet growing demand from China and other emerging countries. It will have two new production lines, allowing the company to go from its current manufacturing capability of 300 million ampoules a year to 600 million in 2013 when it is running at full capacity.

The Boehringer Ingelheim group is among the largest 20 pharmaceutical companies in the world. The company was established in Catalonia in 1952 and, over these years, has evolved to become one of the top 15 companies in the national pharmaceutical sector. The group currently has two international production centers, in Sant Cugat del Vallès (pharmaceutical production) and Malgrat de Mar (fine chemicals).

Sign up for our newsletters

Stay up-to-date on the latest news, events and trends in the BioRegion.